VDR and acute myeloid leukemia: A major limitation of this study is the lack of an in vivo AML model that can recapitulate the vitamin D/VDR/PD-L1 axis, which would validate the above-shown outcomes of MeTC7 treatment in the AML tumor microenvironment.